Showing results (2651-2660 of 2,845) with videos related to
Sort By:
Pageof 285
Brain : a Journal of Neurology|September 14, 2010
Strumpellin is a novel valosin-containing protein binding partner linking hereditary spastic paraplegia to protein aggregation diseasesChristoph S Clemen, Karthikeyan Tangavelou, Karl-Heinz Strucksberg, et al.Journal of Neuropathology and Experimental Neurology|June 20, 2002
Disorganization of the desmin cytoskeleton and mitochondrial dysfunction in plectin-related epidermolysis bullosa simplex with muscular dystrophyRolf Schröder, Wolfram S Kunz, Fatima Rouan, et al.Blood|October 14, 2016
Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphomaJing Du, Martin Neuenschwander, Yong Yu, et al.Diabetes|February 9, 2019
Comparison of Human and Murine Enteroendocrine Cells by Transcriptomic and Peptidomic ProfilingGeoffrey P Roberts, Pierre Larraufie, Paul Richards, et al.Journal of the American Academy of Dermatology|June 21, 2023
Performance measurement part II: A guide to developing dermatology performance measuresDaniella Reimann, Dillon Imbriano, Tatiana Abrantes, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2019
IL-10 Impairs Local Immune Response in Lung Granulomas and Lymph Nodes during Early Mycobacterium tuberculosis InfectionEileen A Wong, Stephanie Evans, Carolyn R Kraus, et al.Molecular Metabolism|September 8, 2020
SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humansHeeyoung Chae, Robert Augustin, Eva Gatineau, et al.Geophysical Research Letters|August 30, 2016
Growth in stratospheric chlorine from short-lived chemicals not controlled by the Montreal ProtocolR Hossaini, M P Chipperfield, A Saiz-Lopez, et al.Cell Metabolism|April 5, 2011
Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemiaPhilipp Kulozik, Allan Jones, Frits Mattijssen, et al.Nature Medicine|February 16, 2024
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trialAndreas H Diacon, Clifton E Barry, Alex Carlton, et al.Pageof 285